Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Alleviating stuttering with pharmacological interventions.

Gerald A Maguire1, Benjamin P Yu, David L Franklin

  • 1University of California, Department of Psychiatry, Route 88, 101 The City Drive South, Irvine Medical Centre, Orange, CA 92868, USA.

Expert Opinion on Pharmacotherapy
|June 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?

Frontiers in human neuroscience·2024
Same author

Stuttering as a spectrum disorder: A hypothesis.

Current research in neurobiology·2023
Same author

A link between seizure and stuttering disorders? A case report.

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists·2023
Same author

Improvement of stuttering after administration of methylphenidate - a case report.

Personalized medicine in psychiatry·2022
Same author

An unexpected iron in the fire of speech production.

Brain : a journal of neurology·2021
Same author

Case Report: Deutetrabenazine as an Adjunctive Treatment for Stuttering.

Frontiers in psychiatry·2021
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Stuttering, a speech disorder, may stem from brain dopamine hyperactivity. Novel dopamine antagonist medications like risperidone and olanzapine show promise in improving stuttering symptoms for clinicians.

Area of Science:

  • Neuroscience
  • Speech-Language Pathology

Background:

  • Stuttering is a common speech disorder involving sound prolongations, repetitions, or blocks.
  • Classified as an Axis I disorder in the DSM-IV, its treatment is often overlooked by physicians.
  • Recent neurophysiological research offers new insights into stuttering and its management.

Purpose of the Study:

  • To explore the neurophysiological underpinnings of stuttering.
  • To identify novel treatment strategies for stuttering based on recent findings.
  • To provide guidance for clinicians in treating stuttering effectively.

Main Methods:

  • Review of current neurophysiological research on stuttering.
  • Investigation into the role of dopamine in stuttering.
  • Analysis of the efficacy of novel dopamine antagonists in stuttering treatment.

Related Experiment Videos

Main Results:

  • Stuttering is potentially linked to dopamine hyperactivity in the brain.
  • Dopamine antagonists, including risperidone and olanzapine, have demonstrated symptom improvement in stuttering.
  • These findings support a neurobiological basis for stuttering treatment.

Conclusions:

  • Dopamine antagonists represent a promising therapeutic avenue for stuttering.
  • Understanding the neurophysiology of stuttering can guide clinical practice.
  • Further research into dopamine modulation may lead to more effective stuttering interventions.